Humanized 3F8 Anti-G(D2) Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial

IMPORTANCE: Chimeric and murine anti-G(D2) antibodies are active against neuroblastoma, but the development of neutralizing antibodies can compromise efficacy. To decrease immunogenicity, hu3F8, a humanized anti-G(D2) antibody, was constructed. OBJECTIVE: To find the maximum-tolerated dose of hu3F8...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Kushner, Brian H., Cheung, Irene Y., Modak, Shakeel, Basu, Ellen M., Roberts, Stephen S., Cheung, Nai-Kong
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2018
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440722/
https://ncbi.nlm.nih.gov/pubmed/30326045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.4005
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars